The Association for Molecular Pathology (AMP) applauds Congress for reaching an agreement on the Consolidated Appropriations Act of 2023 and recognizing that it was not the appropriate mechanism for advancing the Verifying Accurate Leading-edge IVCT Development (VALID) Act. The VALID Act proposed dramatic oversight modifications that would have been disruptive to clinical testing laboratories and harmful to patients throughout the U.S.
↧